Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-154 Dose Formulation A · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
| Arm | Type | Description |
|---|---|---|
| ABBV-154 Dose A | EXPERIMENTAL | Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A. |
| ABBV-154 Dose B | EXPERIMENTAL | Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B. |
| Name | Type | Description |
|---|---|---|
| ABBV-154 Dose Formulation A | DRUG | Subcutaneous Injection |
| ABBV-154 Dose Formulation B | DRUG | Subcutaneous Injection |
Inclusion Criteria: \- Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the nearest tenth at screening and upon initial confinement. Exclusion Criteria: * Participant using any medications, vitamins and/or herbal supplements, within the 2 week period or 5 half-lives (whichever is...
ABBV-154 Dose Formulation A is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) in the immunology therapeutic area. It is a specific subcutaneous injection formulation of ABBV-154 studied in a Phase 1 clinical trial. It has been evaluated in healthy adult participants rather than in patients with a disease indication.
ABBV-154 Dose Formulation A is made and developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie sponsored the Phase 1 study of this subcutaneous injection formulation. The asset sits within AbbVie's immunology therapeutic area.
ABBV-154 Dose Formulation A is in Phase 1 clinical development. Its single recorded trial, NCT05556226, has completed, and no trials of this formulation are currently active. It is an investigational agent and is not approved for any use.
ABBV-154 Dose Formulation A was studied in one Phase 1 trial, NCT05556226, titled a study to assess adverse events and compare how two subcutaneous ABBV-154 injection formulations move through the body of adult healthy participants. The trial enrolled 40 healthy adult volunteers in the United States, was randomized and controlled, and has completed.
ABBV-154 Dose Formulation A has been studied in healthy adult volunteers, not in a patient population, so it has no established therapeutic use. The Phase 1 trial NCT05556226 assessed adverse events and compared how two subcutaneous ABBV-154 injection formulations move through the body. It is an investigational formulation within AbbVie's immunology area.